Novo’s New US Chief on Lilly’s Rival Weight-Loss Pill
Novo Nordisk Executive Vice President for US Operations Jamey Millar discusses the US approval of competitor Eli Lilly's obesity pill, the expansion of the GLP-1 category, and the rollout of a new subscription model. He talks with Katie Greifeld for "The Close." (Source: Bloomberg)
Original Source
Read the full article at Bloomberg →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.